logo

Company History

Company History and Chronology


Greystone


Greystone., was founded in 1996 by Gregory P. Pilant to investigate and commercialize new wound-healing technologies - both natural and synthetic - and license them for distribution.


1995
Greg Pilant, The WoundCare Company’s founder and CEO, is introduced to a wound treatment made from botanical oak bark extract.


2001
More than five years and millions of dollars later, Greystone., isolates the active ingredients in the botanical formulation that are responsible for wound healing. Soon after, Greystone., begins a series of scientific and clinical studies in Europe to investigate the mechanism of action of the products and to test their efficacy and safety in human subjects.


2002
DerMax® is approved as a Class IIa medical device in the EU. After the submission of additional clinical and scientific data, DerMax® is reclassified as a Class IIb medical device. DerMax® is launched in 21 countries.


2005
Epi-Max® is cleared for sale in the United States by the FDA as a combination product governed by the medical device regulation 510(k).

MelMax® is launched in Europe and the Middle East.


2008

Greystone signed a multi-national License Agreement with 3M.


2009

Greystone reorganized and the operations of all the assets of the Company were awarded to 

Presidia Pharmaceuticals.  

Mr. Pilant remains the CEO of Presidia.


2012

The Asian office for the Companies was formed.


2014

The new generation of the technology was developed, and a new patent was filled.


2015

Accellerex was approved for sale in Taiwan.  Biocellerex was formed and has developed many unique technologies utilizing peptides.